We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Spectranetics Completes Acquisition of AngioScore

By HospiMedica International staff writers
Posted on 14 Jul 2014
Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons.

The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated, complementary product lines. The acquisition will diversify Spectranetics’ current product portfolio, which includes a range of ablation laser catheters, support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices. The company also markets a lead management product line that includes excimer laser sheaths, dilator sheaths, mechanical sheaths, and accessories for the removal of pacemaker and defibrillator cardiac leads.

The acquisition will expand physicians’ options for treating critical limb ischemia (CLI), in‐stent restenosis (ISR), calcified lesions, and chronic total occlusions (CTO). Strategically, the combined company will expand Spectranetics’ addressable markets, broaden the product pipeline (including the addition of a proprietary drug‐coated scoring balloon platform), enhance and leverage Spectranetics’ strong sales and marketing capabilities, and drive significant operating efficiencies and savings.

“We are very excited to complete this important transaction. AngioScore meets our criteria with an exceptional strategic fit, leverageable call points, differentiated technology and clear operating efficiencies,” said Scott Drake, President and CEO of Spectranetics. “With AngioScore now a part of our company, we have a meaningfully expanded market opportunity and a compelling product portfolio.”

“Simply put, we are ‘better together.’ We believe that this combination provides an opportunity to build a remarkable future while delivering life‐impacting technologies to physicians and patients,” said Thomas R. Trotter, President and CEO of AngioScore. “In Spectranetics, we find a like‐minded partner that shares our values, our commitment to improving patients’ lives, and equally high standards for operational excellence and quality.”

Related Links:

Spectranetics
AngioScore



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
12-Channel ECG
CM1200B
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Soft-Tissues Biopsy Needle
MR-CLEAR

Latest Business News

Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical

Mindray to Acquire Chinese Medical Device Company APT Medical

Olympus Acquires Korean GI Stent Maker Taewoong Medical